Abstracts tagged "anti-dsDNA"

Abstract Number: 1650 • 2012 ACR/ARHP Annual Meeting
Abnormal Serologies in the Absence of Clinical Activity Do Not Predict New or Recurrent Lupus Nephritis During Pregnancy
Jill P. Buyon¹, Aanam Aslam², Marta M. Guerra², Michael D. Lockshin³, Carl A. Laskin⁴, Ware Branch⁵, Lisa R. Sammaritano⁶, Michelle Petri⁷, Joan T. Merrill⁸, Allen D. Sawitzke⁹ and Jane E. Salmon⁶, ¹Medicine, Division of Rheumatology, New York University School of Medicine, New York, NY, ²Rheumatology 3rd Fl Rsrch, Hospital for Special Surgery, New York, NY, ³Rheumatology, Hospital for Special Surgery, Weill Cornell Medical College, New York, NY, ⁴University of Toronto and LifeQuest Centre for Reproductive Medicine, Toronto, ON, Canada, ⁵Obsterics and Gynecology, Univ of Utah, Salt Lake City, UT, ⁶Rheumatology, Hospital for Special Surgery, New York, NY, ⁷Johns Hopkins University School of Medicine, Baltimore, MD, ⁸Clinical Pharmacology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁹Rheumatology, University of Utah Medical Ctr, Salt Lake City, UT
Background/Purpose: Renal disease is a critical concern of physicians counseling lupus patients regarding pregnancy. In patients without a history of kidney disease, does pregnancy increase…
Abstract Number: 1388 • 2012 ACR/ARHP Annual Meeting
Diagnostic Accuracy of Anti-dsDNA Antibodies in Unselected Patients with Recent Onset of Rheumatic Symptoms
Michele Compagno¹, Søren Jacobsen², Ole Petter Rekvig³, Lennart Truedsson⁴, Niels H. H. Heegaard⁵, Johannes C. Nossent⁶, Andreas Jönsen¹, Rasmus Sleimann Jacobsen⁷, Gro Østli Eilertsen⁶, Gunnar K. Sturfelt⁸ and Anders Bengtsson¹, ¹Department of clinical sciences - Rheumatology, Lund University, Lund, Sweden, ²Department of Rheumatology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark, ³Department of Biochemistry and Medical Biology, University Hospital, Tromsø, Norway, ⁴Department of Laboratory Medicine, Section of Microbiology, Immunology and Glycobiology, Lund University, Lund, Sweden, ⁵Department of Clinical Biochemistry, Immunology & Genetics, Statens Serum Institut, Copenhagen, Denmark, ⁶Dept of Rheumatology, University of Tromsø, Tromso, Norway, ⁷Department of Infectious Diseases and Rheumatology, Section 4242, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark, ⁸Department of Rheumatology, University Hospital Lund, Lund, Sweden
Background/Purpose: Anti-dsDNA antibodies are widely used in diagnostic settings when SLE is suspected. Crithidia Luciliae Immunofluorescence Test (CLIFT) and Enzyme Linked ImmunoSorbent Assay (ELISA) are…

All abstracts accepted to PRYSM are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 6:00 PM CT on March 18. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].